{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:01:47Z","timestamp":1780279307689,"version":"3.54.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04837-2","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:55:52Z","timestamp":1776502552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined anti-VEGF approach in neovascular glaucoma: clinical outcomes of intracameral and intravitreal bevacizumab administration"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3709-1922","authenticated-orcid":false,"given":"Abdulkadir Can","family":"\u00c7\u0131nar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-9603","authenticated-orcid":false,"given":"Ay\u00e7a K\u00fcpeli","family":"\u00c7\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-9753","authenticated-orcid":false,"given":"Ahmet K\u00fcr\u015fad","family":"Sakall\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-9017","authenticated-orcid":false,"given":"R\u00fcveyde","family":"Garip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3021-0493","authenticated-orcid":false,"given":"Hande","family":"G\u00fc\u00e7l\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"3","key":"4837_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4103\/ijo.IJO_1591_20","volume":"69","author":"S Senthil","year":"2021","unstructured":"Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, et al. Neovascular glaucoma - A review. Indian J Ophthalmol. 2021;69(3):525\u201334.","journal-title":"Indian J Ophthalmol"},{"key":"4837_CR2","doi-asserted-by":"crossref","unstructured":"Urbonaviciute D, Buteikiene D, Januleviciene I. A review of neovascular glaucoma: etiology, pathogenesis, diagnosis, and treatment. Med (Kaunas). 2022;58(12).","DOI":"10.3390\/medicina58121870"},{"issue":"3","key":"4837_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1055\/a-1956-9348","volume":"240","author":"D Kalogeropoulos","year":"2023","unstructured":"Kalogeropoulos D, Moussa G, Sung VC, Pappa C, Kalogeropoulos C. Neovascular Glaucoma: An Update. Klin Monbl Augenheilkd. 2023;240(3):305\u201315.","journal-title":"Klin Monbl Augenheilkd"},{"issue":"6","key":"4837_CR4","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1177\/11206721221078678","volume":"32","author":"M Nieves-Moreno","year":"2022","unstructured":"Nieves-Moreno M, Peralta J, Noval S. Neovascular Glaucoma in Children: A case series and a review of the literature. Eur J Ophthalmol. 2022;32(6):3289\u201394.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"4837_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.18240\/ijo.2022.06.20","volume":"15","author":"D Calugaru","year":"2022","unstructured":"Calugaru D, Calugaru M. Etiology, pathogenesis, and diagnosis of neovascular glaucoma. Int J Ophthalmol. 2022;15(6):1005\u201310.","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"4837_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08820530902800801","volume":"24","author":"TA Shazly","year":"2009","unstructured":"Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol. 2009;24(2):113\u201321.","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"4837_CR7","first-page":"315","volume":"65","author":"L Dumbraveanu","year":"2021","unstructured":"Dumbraveanu L, Cusnir V, Bobescu D. A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021;65(4):315\u201329.","journal-title":"Rom J Ophthalmol"},{"issue":"5","key":"4837_CR8","doi-asserted-by":"publisher","first-page":"e051794","DOI":"10.1136\/bmjopen-2021-051794","volume":"12","author":"P Lin","year":"2022","unstructured":"Lin P, Zhao Q, He J, Fan W, He W, Lai M. Comparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysis. BMJ Open. 2022;12(5):e051794.","journal-title":"BMJ Open"},{"key":"4837_CR9","doi-asserted-by":"crossref","unstructured":"Yun JS, Santina A, Tseng VL. Medical and surgical management of neovascular glaucoma. Curr Opin Ophthalmol. 2025.","DOI":"10.1097\/ICU.0000000000001151"},{"issue":"5","key":"4837_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1442-9071.2007.01521.x","volume":"35","author":"MN Chilov","year":"2007","unstructured":"Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2007;35(5):494\u20136.","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"4837_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/IJG.0b013e318170a747","volume":"18","author":"S Duch","year":"2009","unstructured":"Duch S, Buchacra O, Milla E, Andreu D, Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009;18(2):140\u20133.","journal-title":"J Glaucoma"},{"issue":"8","key":"4837_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/IJG.0b013e3181997211","volume":"18","author":"S Yazdani","year":"2009","unstructured":"Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632\u20137.","journal-title":"J Glaucoma"},{"issue":"6","key":"4837_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.18240\/ijo.2021.06.10","volume":"14","author":"F Al Sarireh","year":"2021","unstructured":"Al Sarireh F, Alrawashdeh HM, Al Zubi K, Al Salem K. Role of bevacizumab intraocular injection in the management of neovascular glaucoma. Int J Ophthalmol. 2021;14(6):855\u20139.","journal-title":"Int J Ophthalmol"},{"issue":"9","key":"4837_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/IJG.0b013e3181ccb794","volume":"19","author":"AA Alkawas","year":"2010","unstructured":"Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma. 2010;19(9):622\u20136.","journal-title":"J Glaucoma"},{"issue":"3","key":"4837_CR15","doi-asserted-by":"publisher","first-page":"e080103","DOI":"10.1136\/bmjopen-2023-080103","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Guo YM, Wei J, Min J, Ye L. Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysis. BMJ Open. 2024;14(3):e080103.","journal-title":"BMJ Open"},{"key":"4837_CR16","doi-asserted-by":"crossref","unstructured":"Malika RANL. The challenges of handling neovascular glaucoma at Undaan Eye Hospital Surabaya, Indonesia. Vis Sci Eye Health J. 2023;3(1).","DOI":"10.20473\/vsehj.v3i1.2023.8-11"},{"issue":"3","key":"4837_CR17","first-page":"154","volume":"59","author":"H Ajvazi","year":"2015","unstructured":"Ajvazi H, Lutaj P. Clinical Impact in the Management of Neovascular Glaucoma. Rom J Ophthalmol. 2015;59(3):154\u20138.","journal-title":"Rom J Ophthalmol"},{"issue":"1","key":"4837_CR18","first-page":"24","volume":"59","author":"IR Barac","year":"2015","unstructured":"Barac IR, Pop MD, Gheorghe AI, Taban C. Neovascular Secondary Glaucoma, Etiology and Pathogenesis. Rom J Ophthalmol. 2015;59(1):24\u20138.","journal-title":"Rom J Ophthalmol"},{"key":"4837_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40942-016-0051-x","volume":"2","author":"GB Rodrigues","year":"2016","unstructured":"Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2:26.","journal-title":"Int J Retina Vitreous"},{"key":"4837_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/2090-0686.127340","volume":"106","author":"AMA Khattab","year":"2013","unstructured":"Khattab AMA. Eman. Combined intracameral and intravitreal bevacizumab injection in Neovascular Glaucoma. J Egypt Ophthalmological Soc. 2013;106:117\u201322.","journal-title":"J Egypt Ophthalmological Soc"},{"key":"4837_CR21","doi-asserted-by":"crossref","unstructured":"Sultan S, Siyal N, Waris N, Khokhar R. Intracameral bevacizumab versus subconjunctival bevacizumab in the treatment of neovascular glaucoma. Pakistan J Ophthalmol. 2020;36.","DOI":"10.36351\/pjo.v36i1.993"},{"issue":"2","key":"4837_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5005\/jp-journals-10008-1200","volume":"10","author":"PR Bhagat","year":"2016","unstructured":"Bhagat PR, Agrawal KU, Tandel D. Study of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma. J Curr Glaucoma Pract. 2016;10(2):39\u201348.","journal-title":"J Curr Glaucoma Pract"},{"issue":"6","key":"4837_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3341\/kjo.2017.0017","volume":"31","author":"JY Ha","year":"2017","unstructured":"Ha JY, Lee TH, Sung MS, Park SW. Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma. Korean J Ophthalmol. 2017;31(6):538\u201347.","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"4837_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000327364","volume":"226","author":"A Wolf","year":"2011","unstructured":"Wolf A, von Jagow B, Ulbig M, Haritoglou C. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica. 2011;226(2):51\u20136.","journal-title":"Ophthalmologica"},{"key":"4837_CR25","first-page":"43","volume":"10","author":"HC Kim","year":"2011","unstructured":"Kim HC. Effects of Intravitreal Bevacizumab Injection on Neovascular Glaucoma Korean. J Optometry Vis Sci. 2011;10:43\u201351.","journal-title":"J Optometry Vis Sci"},{"key":"4837_CR26","unstructured":"Pakravan M. Intravitreal bevacizumab for neovascular glaucoma. Acta Ophthalmol Scand. 2007."},{"issue":"2","key":"4837_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00417-022-05785-5","volume":"261","author":"S Ramji","year":"2023","unstructured":"Ramji S, Nagi G, Ansari AS, Kailani O. A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):477\u2013501.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4837_CR28","unstructured":"Yi-Jie C, Xia D, Yan H, Dong J, Ju L, Guo-Jun L, et al. Efficacy of combining treatment based on clinical stage in neovascular glaucoma&nbsp. Ophthalmology in China. 2012;21(4):268\u2009\u2013\u200972."},{"key":"4837_CR29","doi-asserted-by":"crossref","unstructured":"Mayuri TK. Neovascular glaucoma: etiology and staging. New Front Med Med Res. 2021;159\u201368.","DOI":"10.9734\/bpi\/nfmmr\/v16\/3955F"},{"issue":"4","key":"4837_CR30","first-page":"CD007920","volume":"4","author":"T Rittiphairoj","year":"2023","unstructured":"Rittiphairoj T, Roberti G, Michelessi M. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2023;4(4):CD007920.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4837_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-016-0327-9","volume":"16","author":"Y Sun","year":"2016","unstructured":"Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z, et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol. 2016;16(1):150.","journal-title":"BMC Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04837-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04837-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04837-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:49:42Z","timestamp":1780278582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04837-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4837"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04837-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the local Human Clinical Research Ethics Committee (approval number: T\u00dcTF-GOBAEK 2025\/291). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}